News

Media

Conferences

Publications

Clinical

Events

Resources

Operationalizing Treatment with Bispecifics for Multiple Myeloma : Episode 24

Opinion

Video

May 29, 2024

Unmet Needs in Relapsed or Refractory Multiple Myeloma

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Ke Ning, MD

Sarah Rockwell, PharmD, BCOP, and Ke Ning, MD, share their concluding remarks, reflecting on the current landscape and expressing their aspirations for addressing remaining unmet needs.

EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment

EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma

EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies

EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma

EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

EP: 11.Complying with REMS Training and Documentation Requirements

EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

EP: 13.Unmet Needs in Multiple Myeloma Care

EP: 14.Treatment Sequencing and Combination Therapies for MM

EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

EP: 18.Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care

EP: 19.Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics

EP: 20.Considerations for Maintenance Therapy in the Community Oncology Setting

EP: 21.Team Approach to Meeting REMS Program Requirements

EP: 22.Role of Pharmacists in Operationalizing Bispecific Antibodies

EP: 23.Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

Now Viewing

EP: 24.Unmet Needs in Relapsed or Refractory Multiple Myeloma

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!